TR201905101T4 - Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. - Google Patents

Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. Download PDF

Info

Publication number
TR201905101T4
TR201905101T4 TR2019/05101T TR201905101T TR201905101T4 TR 201905101 T4 TR201905101 T4 TR 201905101T4 TR 2019/05101 T TR2019/05101 T TR 2019/05101T TR 201905101 T TR201905101 T TR 201905101T TR 201905101 T4 TR201905101 T4 TR 201905101T4
Authority
TR
Turkey
Prior art keywords
tfpi
monoclonal antibodies
tissue factor
pathway inhibitor
factor pathway
Prior art date
Application number
TR2019/05101T
Other languages
English (en)
Inventor
Wang Zhuozhi
Murphy John
Marquardt Tobias
Moosmayer Dieter
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46932389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201905101(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of TR201905101T4 publication Critical patent/TR201905101T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

İnsan doku faktörü yolak inhibitörünün (TFPI) spesifik epitoplarına bağlanan izole monoklonal antikorlar ve bunları kodlayan izole nükleik asit molekülleri sağlanır. Aynı zamanda anti-TFPI monoklonal antikorları içeren farmasötik bileşimler ve koagülasyondaki yetersizlikler ve kusurların antikorlar uygulanarak tedavi edildiği yöntemler sağlanır.
TR2019/05101T 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar. TR201905101T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161471101P 2011-04-01 2011-04-01

Publications (1)

Publication Number Publication Date
TR201905101T4 true TR201905101T4 (tr) 2019-05-21

Family

ID=46932389

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/05101T TR201905101T4 (tr) 2011-04-01 2012-03-30 Doku faktörü yolak inhibitörüne (TFPI) karşı monoklonal antikorlar.

Country Status (37)

Country Link
US (5) US20140294832A1 (tr)
EP (1) EP2694544B1 (tr)
JP (4) JP6170903B2 (tr)
KR (2) KR101995302B1 (tr)
CN (2) CN103797030B (tr)
AU (3) AU2012236296A1 (tr)
BR (1) BR112013025376A2 (tr)
CA (2) CA2831907C (tr)
CL (1) CL2013002811A1 (tr)
CO (1) CO6890074A2 (tr)
CR (1) CR20130499A (tr)
CU (1) CU20130128A7 (tr)
CY (1) CY1121538T1 (tr)
DK (1) DK2694544T3 (tr)
DO (1) DOP2013000218A (tr)
EA (2) EA034214B1 (tr)
EC (1) ECSP13012913A (tr)
ES (1) ES2722824T3 (tr)
GT (1) GT201300229A (tr)
HK (1) HK1243426A1 (tr)
HR (1) HRP20190467T1 (tr)
HU (1) HUE042706T2 (tr)
IL (4) IL228633B (tr)
LT (1) LT2694544T (tr)
MX (1) MX2013011218A (tr)
MY (2) MY165499A (tr)
PE (1) PE20141149A1 (tr)
PH (4) PH12013502039B1 (tr)
PL (1) PL2694544T3 (tr)
PT (1) PT2694544T (tr)
RS (1) RS58633B1 (tr)
SG (2) SG10201602606UA (tr)
SI (1) SI2694544T1 (tr)
TR (1) TR201905101T4 (tr)
UA (1) UA113623C2 (tr)
WO (1) WO2012135671A2 (tr)
ZA (1) ZA201308169B (tr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010071894A2 (en) 2008-12-19 2010-06-24 Baxter International Inc. Tfpi inhibitors and methods of use
EP2379600B2 (en) † 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
AU2011227714B2 (en) 2010-03-19 2014-09-04 Takeda Pharmaceutical Company Limited TFPI inhibitors and methods of use
PE20141149A1 (es) * 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
WO2013141965A1 (en) 2012-03-21 2013-09-26 Baxter International Inc. Tfpi inhibitors and methods of use
CN104185474B (zh) 2012-03-30 2017-08-25 拜尔健康护理有限责任公司 蛋白酶调节的抗体
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
JP6586016B2 (ja) * 2013-03-15 2019-10-02 ノヴォ ノルディスク アー／エス 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体
PL2970497T3 (pl) 2013-03-15 2018-05-30 Bayer Healthcare Llc Warianty przeciwciał anty-TFPI z różnicowym wiązaniem w zakresie pH dla poprawy farmakokinetyki
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CN106687482B (zh) * 2014-09-17 2022-01-25 诺和诺德股份有限公司 能够结合组织因子途径抑制剂(1-161)上的两个表位的抗体
JP6660957B2 (ja) * 2015-02-25 2020-03-11 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 新規の抗−ｔｆｐｉ抗体及びこれを含む組成物
JP6664467B2 (ja) * 2015-08-19 2020-03-13 ファイザー・インク 組織因子経路インヒビター抗体およびその使用
WO2020021890A1 (ja) * 2018-07-25 2020-01-30 ソニー株式会社 血液凝固系解析装置
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06153985A (ja) * 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
EP2379600B2 (en) * 2008-12-22 2020-10-14 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HUE047173T2 (hu) * 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
PE20141149A1 (es) * 2011-04-01 2014-08-28 Bayer Healthcare Llc Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi)
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) * 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations

Also Published As

Publication number Publication date
AU2019201814A1 (en) 2019-04-04
SG193594A1 (en) 2013-10-30
EP2694544A4 (en) 2015-03-25
PH12013502039A1 (en) 2013-12-16
CN107090046A (zh) 2017-08-25
BR112013025376A2 (pt) 2017-07-25
ZA201308169B (en) 2016-03-30
PH12019500441A1 (en) 2020-10-12
JP6170903B2 (ja) 2017-07-26
EP2694544B1 (en) 2019-01-23
AU2017203105A1 (en) 2017-06-01
US20220041752A1 (en) 2022-02-10
IL274686B (en) 2021-09-30
JP2017113019A (ja) 2017-06-29
CA2831907A1 (en) 2012-10-04
PH12019500439A1 (en) 2020-10-12
JP6363747B2 (ja) 2018-07-25
PL2694544T3 (pl) 2019-07-31
KR20190079698A (ko) 2019-07-05
JP2018172411A (ja) 2018-11-08
CL2013002811A1 (es) 2014-02-28
EA034214B1 (ru) 2020-01-17
AU2012236296A1 (en) 2013-10-24
CA3068997A1 (en) 2012-10-04
PE20141149A1 (es) 2014-08-28
SG10201602606UA (en) 2016-04-28
IL283829A (en) 2021-07-29
EP2694544A2 (en) 2014-02-12
US20140294832A1 (en) 2014-10-02
MX2013011218A (es) 2013-10-17
CO6890074A2 (es) 2014-03-10
CN103797030A (zh) 2014-05-14
ES2722824T3 (es) 2019-08-19
IL257145A (en) 2018-03-29
HRP20190467T1 (hr) 2019-05-03
DK2694544T3 (en) 2019-04-15
CY1121538T1 (el) 2020-05-29
EA201991704A2 (ru) 2020-03-31
IL228633B (en) 2018-03-29
NZ615969A (en) 2016-01-29
JP2014511685A (ja) 2014-05-19
RS58633B1 (sr) 2019-05-31
DOP2013000218A (es) 2013-11-15
KR20140019428A (ko) 2014-02-14
US20190194353A1 (en) 2019-06-27
ECSP13012913A (es) 2014-02-28
CA2831907C (en) 2020-03-24
HK1243426A1 (zh) 2018-07-13
MY165499A (en) 2018-03-27
GT201300229A (es) 2014-11-13
IL274686A (en) 2020-06-30
CU20130128A7 (es) 2014-03-26
CR20130499A (es) 2013-10-24
EA201991704A3 (ru) 2020-06-30
EA201301107A1 (ru) 2014-11-28
IL228633A0 (en) 2013-12-31
MY190951A (en) 2022-05-24
PH12019500440A1 (en) 2020-10-12
HUE042706T2 (hu) 2019-07-29
JP2021019619A (ja) 2021-02-18
US20170107298A1 (en) 2017-04-20
KR101995302B1 (ko) 2019-07-02
WO2012135671A3 (en) 2012-12-13
SI2694544T1 (sl) 2019-06-28
PH12013502039B1 (en) 2013-12-16
US20180194857A1 (en) 2018-07-12
PT2694544T (pt) 2019-04-02
CN103797030B (zh) 2017-05-31
LT2694544T (lt) 2019-04-25
WO2012135671A2 (en) 2012-10-04
UA113623C2 (uk) 2017-02-27

Similar Documents

Publication Publication Date Title
PH12019500439A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201492101A1 (ru) Антитела против fcrn
EA201791186A1 (ru) Антитела к cd38
UA109278C2 (uk) Лікарські засоби, які індукують апоптоз, для лікування раку і імунних і аутоімунних захворювань
UA107706C2 (uk) Апоптоз-індукуючий засіб для лікування раку й імунних і аутоімунних захворювань
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
GB201109238D0 (en) Antibodies
EA201390117A1 (ru) Композиция антител к vegfr-3